Table 1.

FDA approvals of ICIs from January 2011 to May 2021.

Drug Name	Active Ingredient	Approval Date	Mechanism of Action	Company	First Approved Indications
Yervoy	Ipilimumab	25 March 2011	CTLA-4-blocker	Bristol-Myers Squibb	Late-Stage Melanoma
Keytruda	Pembrolizumab	4 September 2014	PD-1 blocker	Merck & Co., Inc.	Advanced or unresectable melanoma
Opdivo	Nivolumab	22 December 2014	PD-1 blocker	Bristol-Myers Squibb	Unresectable or metastatic melanoma
Tecentriq	Atezolizumab	18 May 2016	PD-L1 blocker	Genentech Inc.	Urothelial carcinoma, the most common type of bladder cancer
Bavencio	Avelumab	23 March 2017	PD-L1 blocker	Emd Serono Inc.	Metastatic Merkel cell carcinoma
Imfinzi	Durvalumab	1 May 2017	PD-L1 blocker	Astrazeneca	Locally advanced or metastatic urothelial carcinoma
Libtayo	Cemiplimab-rwlc	28 September 2017	PD-1 blocker	Regeneron Pharmaceuticals	Cutaneous squamous cell carcinoma
Jemperli	Dostarlimab-gxly	22 April 2021	PD-1 blocker	GlaxoSmithKline	Endometrial cancer

CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, Programmed cell death protein 1; PD-L1, Programmed death-ligand 1.